MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New Treatment For Glaucoma

Back to ophthalmology news Blogs list Cancer blog  


Subscribe To Ophthalmology News RSS Feed  RSS content feed What is RSS feed?

New Treatment For Glaucoma




Iowa State University scientists have developed a new technique that successfully treated rats for blindness caused by glaucoma. Their experimental therapy will be used on canine patients in the next year. If proved to be successful, it is expected to move to human trials.

An estimated 3 million people in the U. S. are affected by glaucoma, the second leading cause of blindness in the developed world and the number one cause of vision loss among blacks. People with elevated intraocular pressure are at greatest risk for developing glaucoma.



New Treatment For Glaucoma
(left to right:) Veterinary ophthalmologist Dr. Sinisa Grozdanic, doctoral student Matt Harper and neuroscientist Donald Sakaguchi have developed a new technique that successfully treated rats for blindness caused by glaucoma. (Photo by Bob Elbert)

Iowa State scientists leading the six-year project are Dr. Sinisa Grozdanic, a veterinary ophthalmologist and assistant professor of veterinary clinical sciences; Donald Sakaguchi, neuroscientist and associate professor of genetics, development and cell biology; and Matt Harper, doctoral student in neuroscience. The team also included scientists from the University of Iowa, Yale University, Tulane University and the University of Miami. The work was presented at a recent meeting of the Association for Research in Vision and Ophthalmology Conference.

The scientists previously determined that animals with glaucoma increase production of proteins with neuron-protective capabilities (neurotrophins) in an attempt to shield against blindness. So, they imitated that process in the laboratory, modifying bone marrow-derived stem cells. Then they transplanted the cells into the eyes.

"Once we realized the nature of these self-protective mechanisms, we just tried to mimic the same thing exactly," Grozdanic said. "We used bone-derived stem cells from the patient, modified them to produce the neurotrophin and injected these cells into glaucomatous eyes".

A sophisticated computerized analysis of noninvasive measurements of optic nerve function and the retina's electrical activity showed dramatic improvement in the rats' visual functions after the procedure.

Four years earlier, the scientists had conducted experiments in which biodegradable polymers coated with neuroprotective substances were inserted into the eyes of rats. As the polymer degrades, the neuroprotective substance is released into the eye. The approach worked well, and the same procedure was successful in dogs with optic nerve damage. However, because polymer-based drug delivery generally lasts for only months and glaucoma destroys vision in humans over a period of decades, the researchers shifted their strategy to a longer-lasting approach. They genetically modified the bone marrow stem cells for transplantation so the delivery of the neuroprotective protein can be achieved for years.

"One of the really unique aspects of this approach is that we can isolate these stem cells from the same individual being treated," Sakaguchi said. "It eliminates the ethical issues linked to embryonic stem cells, and the immunological problems of graft rejection".

Grozdanic said the "results were phenomenal." So, the Iowa State team intends to use the technique on dogs as soon as possible.

"Dogs suffer a number of of the same diseases people do and there's a lot of physiological similarity in their eyes and ours," Grozdanic said.

"Four years ago, I was very skeptical that this would work," he said. "Now I see positive results. Hopefully in a few years, we'll be able to say it's working in humans".

The cell biology work and the genetic modification were conducted by Sakaguchi and Harper, while Grozdanic developed techniques for evaluating the molecular changes in the animals. Scientists at the University of Miami provided genetic material for the modification while collaborators at Tulane assisted with culturing the bone marrow stem cells. A biodegradable polymer engineered with neuroprotective substances used in preliminary testing was developed by Erin Lavik at Yale University. Three faculty from the University of Iowa's Department of Ophthalmology and Visual Sciences - Dr. Randy Kardon, Dr. Young Kwon and Dr. Markus Kuehn - helped develop models of elevated eye pressure and assessing visual function. They also compared data from tissue from the rats and dogs to data from human donor tissue to help the team better understand molecular changes caused by glaucoma.


Posted by: Mike    Source




Did you know?
Iowa State University scientists have developed a new technique that successfully treated rats for blindness caused by glaucoma. Their experimental therapy will be used on canine patients in the next year. If proved to be successful, it is expected to move to human trials. An estimated 3 million people in the U. S. are affected by glaucoma, the second leading cause of blindness in the developed world and the number one cause of vision loss among blacks. People with elevated intraocular pressure are at greatest risk for developing glaucoma.

Medicineworld.org: New Treatment For Glaucoma

Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news| Pancreatic cancer news| Prostate cancer news| Endometrial cancer news| General info| What is cancer?| Cancer causes| Is cancer hereditary?| Types of cancer| Cancer statistics| Breast cancer main| Breast cancer symptoms| Colon cancer main| Anal cancer| Bladder cancer main| Lung cancer general| Lung cancer main| Non small cell| Small cell| Ovarian cancer main| Treatment of ovarian cancer| Prostate cancer main| Updates in oncology| Acute myeloid leukemia|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.